As of 2025-05-16, the Intrinsic Value of Tilray Inc (TLRY) is 0.03 USD. This TLRY valuation is based on the model Discounted Cash Flows (EBITDA Exit 10Y). With the current market price of 0.44 USD, the upside of Tilray Inc is -92.3%.

The range of the Intrinsic Value is (0.21) - 0.46 USD.

Is TLRY undervalued or overvalued?

Based on its market price of 0.44 USD and our intrinsic valuation, Tilray Inc (TLRY) is overvalued by 92.3%.

0.44 USD

Stock Price

0.03 USD

Intrinsic Value

Intrinsic Value Details

TLRY Intrinsic Value - Valuation Summary

	Range	Selected	Upside
a
DCF (Growth Exit 5Y)	(9.69) - (2.67)	(4.06)	-1021.6%
DCF (EBITDA Exit 10Y)	(0.21) - 0.46	0.03	-92.3%
Peter Lynch Fair Value	-4.61 - -4.61	-4.61	-1147.9%
P/E Multiples	(15.49) - (19.84)	(18.67)	-4344.0%
EV/EBITDA Multiples	0.08 - 0.24	0.16	-64.7%

TLRY Intrinsic Value - Peers Comparison

	Range	Selected	Upside
a
Corcept Therapeutics Inc	36.66 - 159.02	57.79	-21.2%
Harmony Biosciences Holdings Inc	38.58 - 79.06	50.61	47.9%
Supernus Pharmaceuticals Inc	25.78 - 79.79	38.09	17.3%
Taro Pharmaceutical Industries Ltd	29.83 - 73.9	39.80	-7.4%
Amphastar Pharmaceuticals Inc	30.06 - 58.96	40.40	66.1%
Innoviva Inc	39.8 - 89.06	54.61	197.9%
Trulieve Cannabis Corp	(0.33) - 14.89	1.21	-80.7%
Cronos Group Inc	0.74 - 0.74	0.74	-74.2%
SIGA Technologies Inc	14.6 - 21.58	17.31	192.3%

TLRY Intrinsic Value - Key Valuation Metrics

Market Cap (mil)	451
Beta	0.59
Outstanding shares (mil)	1,026
Enterprise Value (mil)	575

Market risk premium	5.1%
Cost of Equity	8.45%
Cost of Debt	5%
WACC	6.8%